A further strategy is to bridge allo-HSCT after achieving deep molecular remission with CD5/CD7 bispecific CAR-T therapy to reconstitute patients’ immune systems and subsequently achieve long-term leukemia-free survival. Here, CD5 is linked to leukemia.